Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Stephen D. Wilson who wrote (520)	4/1/1998 8:36:00 AM
From: David Israel-Rosen	Read Replies (1) \| Respond to of 1491

have you visited the web lately ? pharmoscorp.com looks like a real web site

To: Stephen D. Wilson who wrote (520)	4/1/1998 10:41:00 AM
From: Ariella	Read Replies (1) \| Respond to of 1491

Dear Stephen: No, I don't think we're going to "languish" in the $2 - $2 1/2 range for the next 4 to 6 months. Softness in stock right now seems normal given the speed with which we climbed. Good volume yesterday is positive and the chart showed good progress for most of the day after the initial selloff. I think we're finding the new trading band and that it will be 2.75 - 3.25, in percentage terms a big advance from the last trading band. It's likely that institutional investors have not really found this stock, so it will take a while for the major upswing to unfold. That said, patience can be helped by remembering a number of positives are due. As posted on the Ariga Portfolio, PARS is gearing up its IR/PR arm and will be holding a meeting for analysts in Tel Aviv next week. Presumably US meetings will follow. Omer Shvili, who writes the Ariga text for Pharmos, says he expects the company to announce its marketing partner for the Lotemax/Alrex rollout at that meeting. The 10-K published yesterday wasn't materially different from the S-3: + As of March 13, 36.30 million shares outstanding. + Lotemax will come to market with the "broadest range of indications of any ophthalmic steroid on the market." + Phase III of LE+T (Lotemax plus the antibiotic tobramycin) to begin in 1998. + As of March 67 of the expected 90 patients enrolled in Phase II of HU-211 trial at 6 medical centers in Israel. Target completion date is by early 1999. + Company has enough funds on hand to "support operations through the first quarter of 1999." The only potential negative I saw in 10-K was that the $50 million-plus in tax loss carryforwards is "as a result of previous business combinations and changes in stock membership" "subject to significant restriction with regards to annual utilization" between year 2000 and 2012. Next person who speaks to the company should clarify this matter and report back. Obviously, the more these carryforwards can be utilized, the better. Other than that, the next months hold more probability of good news than bad: In coming months stock price will get a boost from announcement concerning Lotemax/Alrex rollout, Phase III trial partner for HU-211, Phase III trial for LE-T. If you haven't filled out your PARS position in your portfolio yet, now seems like a good time! Regards, Ariella